Company intelligence / Profile preview
Shanghai Sailon Biotechnology
- Ownership
- Private
- Employees
- ~350
- Development stage
- Other
Overview
Shanghai Sailon Biotechnology is a leading Chinese biopharmaceutical company specializing in the research, development, and production of anti-venom and anti-toxin serums. The company is a dominant player in the domestic market, providing critical treatments for snake bites, scorpion stings, and spider bites. Beyond its core venom-related portfolio, Sailon is expanding into the development of recombinant proteins and other biological products for emergency medicine and infectious diseases. Listed on the Shanghai Stock Exchange's STAR Market, the company maintains a robust manufacturing infrastructure and a specialized R&D focus on niche life-saving therapeutics.
- Therapeutic areas
- OtherInfectious Diseases
- Modalities
- AntibodyAntivenomBiologicRecombinant protein
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Shanghai Sailon Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Sailon Biotechnology.